Please assess the completion status of the following clinical trial:

Trial Title: INTENSE: A Phase I/II Study of INhomogeneous Targeted Dose Escalation in Non-Small CEll Lung Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. 18 years of age~2. ECOG (European Cooperative Oncology Group) performance status 0-2 (0-1 for concurrent chemotherapy)~3. Weight loss \<10% within 3 months of diagnosis~4. Histological diagnosis (biopsy or cytology) of NSCLC (Squamous Cell Carcinoma (SCC), Adenocarcinoma, Large Cell).~   Eligible NSCLC stages: IIA (provided N1); IIB (including T3N0 if unresectable or unsuitable for stereotactic ablative body radiation therapy (SABR)); IIIA and IIIB~5. Inoperable (as per Multi-Disciplinary Team (MDT)) or patient refuses surgery~6. Respiratory function:~   Forced Expiratory Volume (FEV1) ≥ 1L or ≥ 40% of predicted Diffusing Capacity of Lung for Carbon Monoxide (DLCO) ≥ 40%~7. Radiological confirmation of disease via a Positron Emission Tomography (PET) scan prior to registration.~8. Life expectancy, from causes other than lung cancer, of greater than 12 months (as per physician's opinion)~9. Females of child bearing potential (see Appendix H) must not be pregnant and must be prepared to use adequate contraception methods during treatment. Males whose female partners are of child-bearing potential must be prepared to use adequate contraception methods during treatment. Examples of effective contraception methods are a condom or a diaphragm with spermicidal jelly, or oral, injectable or implanted birth control.~10. Provision of written consent in line with ICH-GCP guidelines~Exclusion Criteria:~1. Previous thoracic radiation therapy~2. Known co-existing or prior malignancy which is likely to interfere with treatment or assessment of outcomes~3. Known distant metastases or metastatic pleural effusion~4. Pancoast tumours (tumour of the pulmonary apex)~5. Supraclavicular nodal involvement~6. Spinal cord involvement~7. Patients with syndromes or conditions associated with increased radiosensitivity or development of lung fibrosis~8. Suitable for SABR~9. Idiopathic pulmonary fibrosis/usual interstitial pneumonia~10. Uncontrolled intercurrent illness that is likely to interfere with treatment or assessment of outcomes~11. Psychiatric illness/social situations that would limit compliance with study requirements~12. Pregnant or lactating at the time of proposed randomisation~13. Evidence of any other significant clinical disorder or laboratory finding that makes it undesirable for the patient to participate in the study, or if it is felt by the research / medical team that the patient may not be able to comply with the protocol

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Trial Cohort Description (Type: OTHER): Escalated dose of min 65Gy to the iGTV, with 60Gy to PTV delivered to successive cohorts of patients(pts) until the MTD oesophageal dose is determined. Toxicity will be analysed 2 months post 6pts treated in a cohort.~If: ≤2pts have ≥G3 toxicity, next cohort will be enrolled \& receive escalated dose (an additional +5Gy at each escalation upto max 75Gy)/3 of 6pts have ≥G3 toxicity, a further 6pts will be recruited into that dose level/≥4pts have ≥G3 toxicity, the MTD is fixed at dose level of previous cohort~Cohort is extended to 12pts:~If: ≤4pts have ≥G3 toxicity, next cohort will be enrolled \& receive escalated dose/5 of 12pts have ≥G3 toxicity, the MTD is fixed at that dose level \& recruitment continues up to 24pts/≥6pts have ≥G3 toxicity, the MTD is fixed at the dose level of previous cohort.~Once the max dose cohort is established, recruiting will continue at that dose until 24pts. Concurrent \& neo-adjuvant/no chemotherapy arms will be escalated independently of each other

Based on this trial design, predict the completion outcome and termination type (if applicable).